NewsBenzingaPerspective Therapeutics annonce des données intermédiaires issues de son étude clinique de phase 1/2a en cours sur [212Pb]VMT-α-NET chez des patients atteints de tumeurs neuroendocrines exprimant le récepteur de la somatostatine de type 2, non... Perspective Therapeutics annonce des données intermédiaires issues de son étude clinique de phase 1/2a en cours sur [212Pb]VMT-α-NET chez des patients atteints de tumeurs neuroendocrines exprimant le récepteur de la somatostatine de type 2, non... Benzinga 2026.10.23 14:54 (GMT+0) Open on Benzinga Other news Mark Cuban Says AI Agents Can Be Like ‘Cockroaches’ That Find Ways Into Systems, But Defenders Can Fight Back With AI: ‘We’ve Always Had Hacks’ Nucor Has What It Takes To Capitalize On The Tailwinds In The Steel Market. (NYSE:NUE) Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript China Is Winning Tomorrow, But Losing Today Cathay General Bancorp Stock: Strong ROE Loan Re-Pricing In A Higher Rate (NASDAQ:CATY) Hercules Capital Stock: Close To A Buy, But Not Before 3Q26 (NYSE:HTGC)
Mark Cuban Says AI Agents Can Be Like ‘Cockroaches’ That Find Ways Into Systems, But Defenders Can Fight Back With AI: ‘We’ve Always Had Hacks’
Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript
